Cytotoxicity of Combinations of the Pan-KRAS Inhibitor BAY-293 Against Primary Non-small Lung Cancer Cells

Overview

Journal Transl Oncol

Specialty Oncology

Date 2021 Oct 1

PMID 34598083

Citations 8

Authors

Adelina Plangger

Barbara Rath

Maximilian Hochmair

Martin Funovics

Gerhard Hamilton

Affiliations

Soon will be listed here.

Abstract

KRAS is mutated in approximately 25% of Non-small Cell Lung Cancer (NSCLC) patients and first specific inhibitors showed promising responses that may be improved by concurrent interference with downstream signaling pathways. Cell lines exhibiting KRAS mutations show specific sensitivities to modulators affecting glucose utilization, signal transduction and cell survival. Novel SOS1-directed inhibitors with a broader anticancer coverage such as BAY-293 and BI-3406 inhibit KRAS through the hindrance of SOS1-KRAS interactions. The aim of this study was to check the putative synergy of BAY-293 with modulators having revealed specific vulnerabilities of KRAS-mutated cell lines. The present investigation tested the cytotoxicity of BAY-293 combinations against a series of Osimertinib-resistant primary NSCLC cell lines using MTT tests and calculation of combination indices according to the Chou-Talalay method. The results show that BAY-293 synergizes with modulators of glucose metabolism, inhibitors of cellular proliferation, several chemotherapeutics and a range of diverse modulators, thus corroborating the chemosensitivities of cells expressing mutated KRAS. In conclusion, BAY-293 exerts cytotoxicity with a wide range of drugs against Osimertinib-resistant primary NSCLC cell lines. The administration of pan-KRAS inhibitors alone may be limited in vivo by toxicity to normal tissues but made feasible by its use as part of suitable drug combinations. This study shows that BAY-293 combinations are active against NSCLC cells not further amenable to mutated EGFR-directed targeted therapy and results likewise hold relevance for pancreatic and colon cancer.

Citing Articles

Dual inhibition of HERs and PD-1 counteract resistance in KRAS-mutant head and neck cancer.

Novoplansky O, Jagadeeshan S, Prasad M, Yegodayev K, Marripati D, Shareb R J Exp Clin Cancer Res. 2024; 43(1):308.

PMID: 39567998 PMC: 11577641. DOI: 10.1186/s13046-024-03227-0.

Integration of signaling pathway and bromodomain and extra-terminal domain inhibition for the treatment of mutant Kirsten rat sarcoma viral oncogene homolog cancer.

Hamilton G, Stickler S, Rath B Explor Target Antitumor Ther. 2023; 4(5):1027-1038.

PMID: 38023987 PMC: 10651355. DOI: 10.37349/etat.2023.00178.

The current landscape of using direct inhibitors to target KRAS-mutated NSCLC.

Batrash F, Kutmah M, Zhang J Exp Hematol Oncol. 2023; 12(1):93.

PMID: 37925476 PMC: 10625227. DOI: 10.1186/s40164-023-00453-8.

Critical requirement of SOS1 for tumor development and microenvironment modulation in KRAS-driven lung adenocarcinoma.

Baltanas F, Garcia-Navas R, Rodriguez-Ramos P, Calzada N, Cuesta C, Borrajo J Nat Commun. 2023; 14(1):5856.

PMID: 37730692 PMC: 10511506. DOI: 10.1038/s41467-023-41583-1.

Cancer immune evasion through KRAS and PD-L1 and potential therapeutic interventions.

Watterson A, Coelho M Cell Commun Signal. 2023; 21(1):45.

PMID: 36864508 PMC: 9979509. DOI: 10.1186/s12964-023-01063-x.

References

Tolcher A, Khan K, Ong M, Banerji U, Papadimitrakopoulou V, Gandara D . Antitumor activity in RAS-driven tumors by blocking AKT and MEK. Clin Cancer Res. 2014; 21(4):739-48. PMC: 4335074. DOI: 10.1158/1078-0432.CCR-14-1901. View

Vigil D, Cherfils J, Rossman K, Der C . Ras superfamily GEFs and GAPs: validated and tractable targets for cancer therapy?. Nat Rev Cancer. 2010; 10(12):842-57. PMC: 3124093. DOI: 10.1038/nrc2960. View

Tao Z, Le Blanc J, Wang C, Zhan T, Zhuang H, Wang P . Coadministration of Trametinib and Palbociclib Radiosensitizes KRAS-Mutant Non-Small Cell Lung Cancers In Vitro and In Vivo. Clin Cancer Res. 2016; 22(1):122-33. DOI: 10.1158/1078-0432.CCR-15-0589. View

Alessi D, Cuenda A, Cohen P, Dudley D, Saltiel A . PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo. J Biol Chem. 1995; 270(46):27489-94. DOI: 10.1074/jbc.270.46.27489. View

Acquaviva J, Smith D, Sang J, Friedland J, He S, Sequeira M . Targeting KRAS-mutant non-small cell lung cancer with the Hsp90 inhibitor ganetespib. Mol Cancer Ther. 2012; 11(12):2633-43. DOI: 10.1158/1535-7163.MCT-12-0615. View

Tao S, Wang S, Moghaddam S, Ooi A, Chapman E, Wong P . Oncogenic KRAS confers chemoresistance by upregulating NRF2. Cancer Res. 2014; 74(24):7430-41. PMC: 4268230. DOI: 10.1158/0008-5472.CAN-14-1439. View

Iams W, Lovly C . Molecular Pathways: Clinical Applications and Future Direction of Insulin-like Growth Factor-1 Receptor Pathway Blockade. Clin Cancer Res. 2015; 21(19):4270-7. PMC: 4593065. DOI: 10.1158/1078-0432.CCR-14-2518. View

Puyol M, Martin A, Dubus P, Mulero F, Pizcueta P, Khan G . A synthetic lethal interaction between K-Ras oncogenes and Cdk4 unveils a therapeutic strategy for non-small cell lung carcinoma. Cancer Cell. 2010; 18(1):63-73. DOI: 10.1016/j.ccr.2010.05.025. View

Downward J . Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer. 2003; 3(1):11-22. DOI: 10.1038/nrc969. View

10.

Gillson J, Ramaswamy Y, Singh G, Gorfe A, Pavlakis N, Samra J . Small Molecule KRAS Inhibitors: The Future for Targeted Pancreatic Cancer Therapy?. Cancers (Basel). 2020; 12(5). PMC: 7281596. DOI: 10.3390/cancers12051341. View

11.

Romero R, Sayin V, Davidson S, Bauer M, Singh S, LeBoeuf S . Keap1 loss promotes Kras-driven lung cancer and results in dependence on glutaminolysis. Nat Med. 2017; 23(11):1362-1368. PMC: 5677540. DOI: 10.1038/nm.4407. View

12.

Hutton J, Wang X, Zimmerman L, Slebos R, Trenary I, Young J . Oncogenic KRAS and BRAF Drive Metabolic Reprogramming in Colorectal Cancer. Mol Cell Proteomics. 2016; 15(9):2924-38. PMC: 5013308. DOI: 10.1074/mcp.M116.058925. View

13.

Otto C, Schmidt S, Kastner C, Denk S, Kettler J, Muller N . Targeting bromodomain-containing protein 4 (BRD4) inhibits MYC expression in colorectal cancer cells. Neoplasia. 2019; 21(11):1110-1120. PMC: 6888720. DOI: 10.1016/j.neo.2019.10.003. View

14.

Okumura S, Janne P . Molecular pathways: the basis for rational combination using MEK inhibitors in KRAS-mutant cancers. Clin Cancer Res. 2014; 20(16):4193-9. DOI: 10.1158/1078-0432.CCR-13-2365. View

15.

Steckel M, Molina-Arcas M, Weigelt B, Marani M, Warne P, Kuznetsov H . Determination of synthetic lethal interactions in KRAS oncogene-dependent cancer cells reveals novel therapeutic targeting strategies. Cell Res. 2012; 22(8):1227-45. PMC: 3411175. DOI: 10.1038/cr.2012.82. View

16.

Lugowska I, Kosela-Paterczyk H, Kozak K, Rutkowski P . Trametinib: a MEK inhibitor for management of metastatic melanoma. Onco Targets Ther. 2015; 8:2251-9. PMC: 4556032. DOI: 10.2147/OTT.S72951. View

17.

Christofk H, Vander Heiden M, Harris M, Ramanathan A, Gerszten R, Wei R . The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature. 2008; 452(7184):230-3. DOI: 10.1038/nature06734. View

18.

Scheffzek K, Ahmadian M, Kabsch W, Wiesmuller L, Lautwein A, Schmitz F . The Ras-RasGAP complex: structural basis for GTPase activation and its loss in oncogenic Ras mutants. Science. 1997; 277(5324):333-8. DOI: 10.1126/science.277.5324.333. View

19.

Wang H, Wang L, Zhang Y, Wang J, Deng Y, Lin D . Inhibition of glycolytic enzyme hexokinase II (HK2) suppresses lung tumor growth. Cancer Cell Int. 2016; 16:9. PMC: 4755025. DOI: 10.1186/s12935-016-0280-y. View

20.

Janes M, Zhang J, Li L, Hansen R, Peters U, Guo X . Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor. Cell. 2018; 172(3):578-589.e17. DOI: 10.1016/j.cell.2018.01.006. View